Literature DB >> 25988898

TET1: an epigenetic guardian of lymphomagenesis.

Kasper Dindler Rasmussen1, Kristian Helin2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25988898     DOI: 10.1038/ni.3176

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  9 in total

1.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23).

Authors:  R B Lorsbach; J Moore; S Mathew; S C Raimondi; S T Mukatira; J R Downing
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

2.  DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction.

Authors:  Ann-Marie Bröske; Lena Vockentanz; Shabnam Kharazi; Matthew R Huska; Elena Mancini; Marina Scheller; Christiane Kuhl; Andreas Enns; Marco Prinz; Rudolf Jaenisch; Claus Nerlov; Achim Leutz; Miguel A Andrade-Navarro; Sten Eirik W Jacobsen; Frank Rosenbauer
Journal:  Nat Genet       Date:  2009-10-04       Impact factor: 38.330

Review 3.  DNA methylation: TET proteins-guardians of CpG islands?

Authors:  Kristine Williams; Jesper Christensen; Kristian Helin
Journal:  EMBO Rep       Date:  2011-12-23       Impact factor: 8.807

4.  TET1 is a tumor suppressor of hematopoietic malignancy.

Authors:  Luisa Cimmino; Meelad M Dawlaty; Delphine Ndiaye-Lobry; Yoon Sing Yap; Sofia Bakogianni; Yiting Yu; Sanchari Bhattacharyya; Rita Shaknovich; Huimin Geng; Camille Lobry; Jasper Mullenders; Bryan King; Thomas Trimarchi; Beatriz Aranda-Orgilles; Cynthia Liu; Steven Shen; Amit K Verma; Rudolf Jaenisch; Iannis Aifantis
Journal:  Nat Immunol       Date:  2015-04-13       Impact factor: 25.606

5.  Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation.

Authors:  Bo-Kuan Wu; Charles Brenner
Journal:  Cell Rep       Date:  2014-11-26       Impact factor: 9.423

6.  Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Kendell Clement; Michael J Ziller; Patrick Boyle; Jean Fan; Hongcang Gu; Kristen Stevenson; Carrie Sougnez; Lili Wang; Shuqiang Li; Dylan Kotliar; Wandi Zhang; Mahmoud Ghandi; Levi Garraway; Stacey M Fernandes; Kenneth J Livak; Stacey Gabriel; Andreas Gnirke; Eric S Lander; Jennifer R Brown; Donna Neuberg; Peter V Kharchenko; Nir Hacohen; Gad Getz; Alexander Meissner; Catherine J Wu
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

7.  LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23).

Authors:  Ryoichi Ono; Tomohiko Taki; Takeshi Taketani; Masafumi Taniwaki; Hajime Kobayashi; Yasuhide Hayashi
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

Review 8.  The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.

Authors:  E Solary; O A Bernard; A Tefferi; F Fuks; W Vainchenker
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

9.  TET1 plays an essential oncogenic role in MLL-rearranged leukemia.

Authors:  Hao Huang; Xi Jiang; Zejuan Li; Yuanyuan Li; Chun-Xiao Song; Chunjiang He; Miao Sun; Ping Chen; Sandeep Gurbuxani; Jiapeng Wang; Gia-Ming Hong; Abdel G Elkahloun; Stephen Arnovitz; Jinhua Wang; Keith Szulwach; Li Lin; Craig Street; Mark Wunderlich; Meelad Dawlaty; Mary Beth Neilly; Rudolf Jaenisch; Feng-Chun Yang; James C Mulloy; Peng Jin; Paul P Liu; Janet D Rowley; Mingjiang Xu; Chuan He; Jianjun Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 12.779

  9 in total
  3 in total

Review 1.  A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro.

Authors:  Craig L Parfett; Daniel Desaulniers
Journal:  Int J Mol Sci       Date:  2017-06-01       Impact factor: 5.923

2.  MiR-29b/TET1/ZEB2 signaling axis regulates metastatic properties and epithelial-mesenchymal transition in breast cancer cells.

Authors:  Hua Wang; Xinglan An; Hao Yu; Sheng Zhang; Bo Tang; Xueming Zhang; Ziyi Li
Journal:  Oncotarget       Date:  2017-10-31

Review 3.  Physiological and pathological implications of 5-hydroxymethylcytosine in diseases.

Authors:  Jing Liang; Fan Yang; Liang Zhao; Chongwei Bi; Benzhi Cai
Journal:  Oncotarget       Date:  2016-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.